SILUMBRA suvorexant 15mg tablet blister pack

Country: Australia

Bahasa: Inggeris

Sumber: Department of Health (Therapeutic Goods Administration)

Beli sekarang

Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
27-11-2017

Bahan aktif:

suvorexant, Quantity: 15 mg

Boleh didapati daripada:

Merck Sharp & Dohme (Australia) Pty Ltd

INN (Nama Antarabangsa):

suvorexant

Borang farmaseutikal:

Tablet, film coated

Komposisi:

Excipient Ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; lactose monohydrate; copovidone; titanium dioxide; hypromellose; triacetin

Laluan pentadbiran:

Oral

Unit dalam pakej:

3 tablets, 10 tablets, 30 tablets

Jenis preskripsi:

(S4) Prescription Only Medicine

Tanda-tanda terapeutik:

SILUMBRA is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Following initiation of treatment, continuation should be re-evaluated after 3 months [see Pharmacodynamic Properties, Clinical trials and Adverse Effects (Undesirable Effects) for clinical trial durations].

Ringkasan produk:

Visual Identification: White, oval, biconvex, film coated tablet, marked with MSD logo and 325 on one side and plain on the other side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status kebenaran:

Registered

Tarikh kebenaran:

2016-11-16